Medication-assisted treatment for opioid addiction: Methadone and buprenorphine
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Among agents for opioid addiction treatment, methadone is a full μ-opioid receptor agonist, whereas buprenorphine is a partial agonist. Both are long-acting agents. Buprenorphine has a superior safety profile. Methadone is formulated for oral administration and buprenorphine is formulated for sublingual administration. The U.S. Food and Drug Administration is considering for approval a subdermal buprenorphine implant that has a six-month duration of action. Both medications reduce mortality rates and improve other outcomes. Data from a recent randomized, controlled comparison study (N = 1269) of both medications show better treatment retention with methadone, but reduced illicit opioid use early in treatment with buprenorphine. Risk behaviors for human immunodeficiency virus (HIV) were measured by using the Risk Behavior Survey at baseline, at 12 weeks, and at 24 weeks for study completers. In the 30 days prior to entering treatment, 14.4% of the completers (n = 340) who were randomized to treatment with buprenorphine had shared needles and 14.1% of the completers (n = 391) who were randomized to methadone treatment had shared needles. In the 30 days prior to Week 24, the percentage of patients sharing needles decreased to 2.4% for the buprenorphine group and 4.8% for the methadone group (p < 0.0001). In the 30 days prior to entering treatment, 6.8% of the completers randomized to buprenorphine and 8.2% of the completers randomized to methadone had multiple sexual partners; at Week 24, only 5.2% and 5.1%, respectively, reported multiple partners (p < 0.04).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical pharmacology of buprenorphine: Ceiling effects at high doses
Walsh, S. L., Preston, K. L., Stitzer, M. L., Cone, E. J., & Bigelow, G. E. (1994) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1994.71 · Cited by 773 · cited 1×
“As a partial μ-opioid agonist, it has a ceiling effect on its activity, such that after a modest dosage is received, further doses do not lead to increasing effects and, thus, the risk of respiratory depression and overdose is very low [10,11].”
BackgroundKakko, J., Svanborg, K. D., Kreek, M. J., & Heilig, M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12600-1 · Cited by 466
Hser, Y., Saxon, A. J., Huang, D., Hasson, A., Thomas, C., Hillhouse, M., Jacobs, P., Teruya, C., McLaughlin, P., Wiest, K., et al. (2014) · Addiction · doi:10.1111/add.12333 · Cited by 455
Self-citationGreenwald, M. K., Johanson, C.-E., Moody, D. E., Woods, J. H., Kilbourn, M. R., Koeppe, R. A., Schuster, C. R., & Zubieta, J.-K. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300251 · Cited by 320
Cited by
Prescription opioid exposures among children and adolescents in the United States: 2000–2015.
Allen, J. D., Casavant, M. J., Spiller, H. A., Chounthirath, T., Hodges, N. L., & Smith, G. A. (2017) · Pediatrics · doi:10.1542/peds.2016-3382 · Cited by 156
Craving in Opioid Use Disorder: From Neurobiology to Clinical Practice
Kakko, J., Alho, H., Baldacchino, A., Molina, R., Nava, F. A., & Shaya, G. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00592 · Cited by 140
Kirby, K. C., Carpenedo, C. M., Dugosh, K. L., Rosenwasser, B. J., Benishek, L. A., Janik, A., Keashen, R., Bresani, E., & Silverman, K. (2013) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2013.04.015 · Cited by 20
Metadata
- Authors
- Saxon, A. J., Hser, Y.-I., Woody, G., & Ling, W.
- Venue
- Journal of Food and Drug Analysis
- Published
- 2013-12
- Volume
- 21
- Issue
- 4
- Pages
- S69-S72
- ISSN
- 1021-9498 (ISSN-L)
- OpenAlex
- W2079622133
- Cited by
- 69
- References
- 4
- FWCI
- 2.84
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.